ABO 2102
/ Suzhou Abogen Biosci
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
November 01, 2024
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Advanced Pancreatic Cancer
(clinicaltrials.gov)
- P1 | N=56 | Recruiting | Sponsor: Ruijin Hospital | Not yet recruiting ➔ Recruiting
Enrollment open • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
August 29, 2024
Study of KRAS Neoantigen mRNA Vaccine (ABO2102) in Patients With KRAS -Mutated Advanced Pancreatic Cancer
(clinicaltrials.gov)
- P1 | N=56 | Not yet recruiting | Sponsor: Ruijin Hospital
IO biomarker • Metastases • New P1 trial • Gastrointestinal Cancer • Hepatology • Oncology • Pancreatic Cancer • Solid Tumor
1 to 2
Of
2
Go to page
1